KPTI Description — Karyopharm Therapeutics Inc
Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
Free KPTI Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.57 out of 4) 61st percentile
(ranked higher than approx. 61% of all stocks covered)
Analysts Forecast: KPTI Price Target Based on data provided by Zacks Investment Research via Quandl.com |
|